通化金马：公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病

Core Viewpoint - Tonghua Golden Horse has developed a Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, primarily for the treatment of mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress reported as normal. Major information regarding the new drug will be disclosed through designated media outlets [2]. Company Summary - The new drug, Amber Dihydroaminoacridine Tablets, is aimed at treating mild to moderate Alzheimer's disease [2]. - The company has completed the comprehensive review process for the new drug and is now in the final review phase [2]. - All progress related to the new drug is reported to be on track, indicating a positive development timeline [2].